ArticleJournal of the National Cancer Institute2012

CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.

Catherine M Kelly et al.PubMed ↗Publisher ↗

No numbers read from the abstract.